Drugs / Bacitracin zinc
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NEO-POLYCIN | — | 1954-04-19 | fda.gov ↗ |
Trials 1
1953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT07698938 | Feb → Mar 2025 | — | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT00000635 Background | ? → Apr 1992 | HIV infectious disease, herpes simplex infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacitracin zinc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07698938 ↗ |
| Route | Topical | “Polymyxin B sulfate/bacitracin zinc ointment is then applied over the trifluridine.” NCT00000635 ↗ |